Kálvin Beáta, Fekésházy Attila, Lengyel Zsolt, Szakáll Szabolcs, Agoston Péter, Lengyel Erzsébet, Székely Judit, Várady Erika, Galuska László, Trón Lajos, Esik Olga
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, PET Centrum, Debrecen.
Orv Hetil. 2002 May 26;143(21 Suppl 3):1255-61.
The authors have reviewed the financial considerations of oncological FDG PET examinations by the guidelines of the Health Care Financing Administration (USA). By critical assessment of large number of clinical investigations, the cost-effectiveness of FDG PET scans has been confirmed in the following cases: differential diagnosis of solitary pulmonary nodule, diagnosis, staging and restaging of non-small cell lung cancer, colorectal cancer, malignant lymphomas, melanoma malignum, esophageal neoplasms and cancers of the head and neck. The role of this method in breast cancer is currently under intensive investigation. Due to the correct staging, PET examinations in these indications enable the clinicians to choose the optimal treatment ensuring the maximum probability of recovery and being cost-effective as unnecessary medical interventions become avoidable.
作者根据美国医疗保健财务管理局的指南，回顾了肿瘤学FDG PET检查的财务考量因素。通过对大量临床研究的批判性评估，FDG PET扫描在以下情况中的成本效益已得到证实：孤立性肺结节的鉴别诊断、非小细胞肺癌、结直肠癌、恶性淋巴瘤、恶性黑色素瘤、食管肿瘤以及头颈部癌症的诊断、分期和再分期。该方法在乳腺癌中的作用目前正在深入研究中。由于分期准确，这些适应症的PET检查使临床医生能够选择最佳治疗方案，确保最大的康复概率并具有成本效益，因为可以避免不必要的医疗干预。
